Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Free Cash Flow (2018 - 2025)

TransMedics has reported Free Cash Flow over the past 8 years, most recently at $34.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $34.5 million for Q4 2025, up 470.38% from a year ago — trailing twelve months through Dec 2025 was $191.1 million (up 336.08% YoY), and the annual figure for FY2025 was $191.1 million, up 336.08%.
  • Free Cash Flow for Q4 2025 was $34.5 million at TransMedics, down from $69.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TMDX hit a ceiling of $115.9 million in Q4 2023 and a floor of -$116.8 million in Q3 2023.
  • Median Free Cash Flow over the past 5 years was -$6.6 million (2021), compared with a mean of $820100.0.
  • Peak annual rise in Free Cash Flow hit 3754.34% in 2023, while the deepest fall reached 1198.79% in 2023.
  • TransMedics' Free Cash Flow stood at -$9.8 million in 2021, then surged by 67.73% to -$3.2 million in 2022, then surged by 3754.34% to $115.9 million in 2023, then crashed by 94.77% to $6.1 million in 2024, then skyrocketed by 470.38% to $34.5 million in 2025.
  • The last three reported values for Free Cash Flow were $34.5 million (Q4 2025), $69.0 million (Q3 2025), and $91.5 million (Q2 2025) per Business Quant data.